

# Niklas Mattsson

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/6647443/niklas-mattsson-publications-by-citations.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

272  
papers

15,022  
citations

62  
h-index

115  
g-index

311  
ext. papers

19,929  
ext. citations

7  
avg, IF

6.7  
L-index

#	Paper	IF	Citations
272	Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. <i>JAMA - Journal of the American Medical Association</i> , <b>2015</b> , 313, 1924-38	27.4	842
271	CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. <i>JAMA - Journal of the American Medical Association</i> , <b>2009</b> , 302, 385-93	27.4	758
270	Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease. <i>JAMA Neurology</i> , <b>2017</b> , 74, 557-566	17.2	435
269	Earliest accumulation of $\beta$ amyloid occurs within the default-mode network and concurrently affects brain connectivity. <i>Nature Communications</i> , <b>2017</b> , 8, 1214	17.4	348
268	Amyloid biomarkers in Alzheimer's disease. <i>Trends in Pharmacological Sciences</i> , <b>2015</b> , 36, 297-309	13.2	320
267	Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers. <i>Lancet Neurology, The</i> , <b>2017</b> , 16, 661-676	24.1	308
266	Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia. <i>Nature Medicine</i> , <b>2020</b> , 26, 379-386	50.5	292
265	The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. <i>Alzheimer's and Dementia</i> , <b>2011</b> , 7, 386-395.e6	1.2	291
264	CSF biomarker variability in the Alzheimer's Association quality control program. <i>Alzheimer's and Dementia</i> , <b>2013</b> , 9, 251-61	1.2	289
263	Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. <i>Lancet Neurology, The</i> , <b>2020</b> , 19, 422-433	24.1	286
262	Plasma tau in Alzheimer disease. <i>Neurology</i> , <b>2016</b> , 87, 1827-1835	6.5	269
261	Discriminative Accuracy of Plasma Phospho-tau217 For Alzheimer Disease vs Other Neurodegenerative Disorders. <i>JAMA - Journal of the American Medical Association</i> , <b>2020</b> , 324, 772-781	27.4	268
260	Association of Cerebrospinal Fluid Neurofilament Light Concentration With Alzheimer Disease Progression. <i>JAMA Neurology</i> , <b>2016</b> , 73, 60-7	17.2	258
259	CSF A $\beta$ 2/A $\beta$ 0 and A $\beta$ 2/A $\beta$ 8 ratios: better diagnostic markers of Alzheimer disease. <i>Annals of Clinical and Translational Neurology</i> , <b>2016</b> , 3, 154-65	5.3	244
258	Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis. <i>JAMA Neurology</i> , <b>2019</b> , 76, 1035-1048	17.2	237
257	Cerebrospinal fluid analysis detects cerebral amyloid- $\beta$ accumulation earlier than positron emission tomography. <i>Brain</i> , <b>2016</b> , 139, 1226-36	11.2	229
256	Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease. <i>JAMA Neurology</i> , <b>2019</b> , 76, 791-799	17.2	228

255	The cerebrospinal fluid "Alzheimer profile": easily said, but what does it mean?. <i>Alzheimer's and Dementia</i> , <b>2014</b> , 10, 713-723.e2	1.2	204
254	Smoking and increased Alzheimer's disease risk: a review of potential mechanisms. <i>Alzheimer's and Dementia</i> , <b>2014</b> , 10, S122-45	1.2	194
253	Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease. <i>Neurology</i> , <b>2015</b> , 85, 1240-9	6.5	192
252	Serum neurofilament light protein predicts clinical outcome in traumatic brain injury. <i>Scientific Reports</i> , <b>2016</b> , 6, 36791	4.9	186
251	CSF neurofilament light differs in neurodegenerative diseases and predicts severity and survival. <i>Neurology</i> , <b>2014</b> , 83, 1945-53	6.5	186
250	Discriminative Accuracy of [18F]flortaucipir Positron Emission Tomography for Alzheimer Disease vs Other Neurodegenerative Disorders. <i>JAMA - Journal of the American Medical Association</i> , <b>2018</b> , 320, 1151-1162	27.4	173
249	Independent information from cerebrospinal fluid amyloid- $\beta$ and florbetapir imaging in Alzheimer's disease. <i>Brain</i> , <b>2015</b> , 138, 772-83	11.2	169
248	Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer's disease. <i>Brain</i> , <b>2015</b> , 138, 3373-85	11.2	165
247	Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease-Related $\beta$ Amyloid Status. <i>JAMA Neurology</i> , <b>2019</b> , 76, 1060-1069	17.2	159
246	Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease. <i>EMBO Molecular Medicine</i> , <b>2016</b> , 8, 1184-1196	12	152
245	Reporting standards for studies of diagnostic test accuracy in dementia: The STARDdem Initiative. <i>Neurology</i> , <b>2014</b> , 83, 364-73	6.5	146
244	Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer's disease. <i>Nature Communications</i> , <b>2020</b> , 11, 1683	17.4	133
243	Age and diagnostic performance of Alzheimer disease CSF biomarkers. <i>Neurology</i> , <b>2012</b> , 78, 468-76	6.5	133
242	Diagnostic performance of cerebrospinal fluid total tau and phosphorylated tau in Creutzfeldt-Jakob disease: results from the Swedish Mortality Registry. <i>JAMA Neurology</i> , <b>2014</b> , 71, 476-83	17.2	125
241	Associations between tau, A $\beta$ and cortical thickness with cognition in Alzheimer disease. <i>Neurology</i> , <b>2019</b> , 92, e601-e612	6.5	125
240	F-AV-1451 and CSF T-tau and P-tau as biomarkers in Alzheimer's disease. <i>EMBO Molecular Medicine</i> , <b>2017</b> , 9, 1212-1223	12	124
239	CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease. <i>Neurology</i> , <b>2018</b> , 91, e867-e877	6.5	120
238	Discontinuation of proton pump inhibitors in patients on long-term therapy: a double-blind, placebo-controlled trial. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2006</b> , 24, 945-54	6.1	120

237	Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease. <i>EMBO Molecular Medicine</i> , <b>2019</b> , 11, e11170	12	113
236	Association of brain amyloid- $\beta$ with cerebral perfusion and structure in Alzheimer's disease and mild cognitive impairment. <i>Brain</i> , <b>2014</b> , 137, 1550-61	11.2	109
235	Cerebrospinal fluid tau and amyloid- $\beta$ 42 in patients with dementia. <i>Brain</i> , <b>2015</b> , 138, 2716-31	11.2	105
234	Intra-individual stability of CSF biomarkers for Alzheimer's disease over two years. <i>Journal of Alzheimer's Disease</i> , <b>2007</b> , 12, 255-60	4.3	105
233	Magnetic resonance imaging in Alzheimer's Disease Neuroimaging Initiative 2. <i>Alzheimer's and Dementia</i> , <b>2015</b> , 11, 740-56	1.2	101
232	Biomarkers for tau pathology. <i>Molecular and Cellular Neurosciences</i> , <b>2019</b> , 97, 18-33	4.8	96
231	Association of Cerebral Amyloid- $\beta$ Aggregation With Cognitive Functioning in Persons Without Dementia. <i>JAMA Psychiatry</i> , <b>2018</b> , 75, 84-95	14.5	94
230	Global standardization measurement of cerebral spinal fluid for Alzheimer's disease: an update from the Alzheimer's Association Global Biomarkers Consortium. <i>Alzheimer's and Dementia</i> , <b>2013</b> , 9, 137-40	1.2	93
229	Cerebrospinal fluid microglial markers in Alzheimer's disease: elevated chitotriosidase activity but lack of diagnostic utility. <i>NeuroMolecular Medicine</i> , <b>2011</b> , 13, 151-9	4.6	89
228	A $\beta$ deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer's disease. <i>Science Advances</i> , <b>2020</b> , 6, eaaz2387	14.3	88
227	CSF biomarkers for the differential diagnosis of Alzheimer's disease: A large-scale international multicenter study. <i>Alzheimer's and Dementia</i> , <b>2015</b> , 11, 1306-15	1.2	87
226	Serum Neurofilament Light Chain for Prognosis of Outcome After Cardiac Arrest. <i>JAMA Neurology</i> , <b>2019</b> , 76, 64-71	17.2	85
225	Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer's disease. <i>Annals of Clinical and Translational Neurology</i> , <b>2014</b> , 1, 534-43	5.3	78
224	Prevalence of amyloid- $\beta$ pathology in distinct variants of primary progressive aphasia. <i>Annals of Neurology</i> , <b>2018</b> , 84, 729-740	9.4	74
223	Clinical validity of cerebrospinal fluid A $\beta$ 2, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework. <i>Neurobiology of Aging</i> , <b>2017</b> , 52, 196-213	5.6	73
222	Diagnostic Performance of RO948 F 18 Tau Positron Emission Tomography in the Differentiation of Alzheimer Disease From Other Neurodegenerative Disorders. <i>JAMA Neurology</i> , <b>2020</b> , 77, 955-965	17.2	71
221	Staging $\beta$ Amyloid Pathology With Amyloid Positron Emission Tomography. <i>JAMA Neurology</i> , <b>2019</b> , 76, 1319-1329	17.2	71
220	Revolutionizing Alzheimer's disease and clinical trials through biomarkers. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , <b>2015</b> , 1, 412-9	5.2	66

219	Reference measurement procedures for Alzheimer's disease cerebrospinal fluid biomarkers: definitions and approaches with focus on amyloid $\beta$ 2. <i>Biomarkers in Medicine</i> , <b>2012</b> , 6, 409-17	2.3	66
218	Lysosomal network proteins as potential novel CSF biomarkers for Alzheimer's disease. <i>NeuroMolecular Medicine</i> , <b>2014</b> , 16, 150-60	4.6	65
217	Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease. <i>JAMA Psychiatry</i> , <b>2014</b> , 71, 1183-91	14.5	65
216	An online nano-LC-ESI-FTICR-MS method for comprehensive characterization of endogenous fragments from amyloid $\beta$ and amyloid precursor protein in human and cat cerebrospinal fluid. <i>Journal of Mass Spectrometry</i> , <b>2012</b> , 47, 591-603	2.2	64
215	Longitudinal plasma p-tau217 is increased in early stages of Alzheimer's disease. <i>Brain</i> , <b>2020</b> , 143, 3234-3241	3.4	63
214	Comparing F-AV-1451 with CSF t-tau and p-tau for diagnosis of Alzheimer disease. <i>Neurology</i> , <b>2018</b> , 90, e388-e395	6.5	62
213	Cerebrospinal fluid biomarkers for Alzheimer's disease: diagnostic performance in a homogeneous mono-center population. <i>Journal of Alzheimer's Disease</i> , <b>2011</b> , 24, 537-46	4.3	62
212	Longitudinal cerebrospinal fluid biomarkers over four years in mild cognitive impairment. <i>Journal of Alzheimer's Disease</i> , <b>2012</b> , 30, 767-78	4.3	62
211	Associations of Plasma Phospho-Tau217 Levels With Tau Positron Emission Tomography in Early Alzheimer Disease. <i>JAMA Neurology</i> , <b>2021</b> , 78, 149-156	17.2	62
210	The National Institute on Aging and the Alzheimer's Association Research Framework for Alzheimer's disease: Perspectives from the Research Roundtable. <i>Alzheimer's and Dementia</i> , <b>2018</b> , 14, 563-575	1.2	61
209	The impact of preanalytical variables on measuring cerebrospinal fluid biomarkers for Alzheimer's disease diagnosis: A review. <i>Alzheimer's and Dementia</i> , <b>2018</b> , 14, 1313-1333	1.2	61
208	Cerebrospinal fluid profiles of amyloid $\beta$ -related biomarkers in Alzheimer's disease. <i>NeuroMolecular Medicine</i> , <b>2012</b> , 14, 65-73	4.6	61
207	Novel $\alpha$ isoforms in Alzheimer's disease - their role in diagnosis and treatment. <i>Current Pharmaceutical Design</i> , <b>2011</b> , 17, 2594-602	3.3	60
206	Inter-laboratory variation in cerebrospinal fluid biomarkers for Alzheimer's disease: united we stand, divided we fall. <i>Clinical Chemistry and Laboratory Medicine</i> , <b>2010</b> , 48, 603-7	5.9	60
205	BACE1 inhibition induces a specific cerebrospinal fluid $\beta$ amyloid pattern that identifies drug effects in the central nervous system. <i>PLoS ONE</i> , <b>2012</b> , 7, e31084	3.7	60
204	Bidirectional links between Alzheimer's disease and Niemann-Pick type C disease. <i>Neurobiology of Disease</i> , <b>2014</b> , 72 Pt A, 37-47	7.5	59
203	Multiplex proteomics identifies novel CSF and plasma biomarkers of early Alzheimer's disease. <i>Acta Neuropathologica Communications</i> , <b>2019</b> , 7, 169	7.3	58
202	Gamma-secretase-dependent amyloid-beta is increased in Niemann-Pick type C: a cross-sectional study. <i>Neurology</i> , <b>2011</b> , 76, 366-72	6.5	58

201	Multiple comorbid neuropathologies in the setting of Alzheimer's disease neuropathology and implications for drug development. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , <b>2017</b> , 3, 83-91	6	57
200	Prediction of future Alzheimer's disease dementia using plasma phospho-tau combined with other accessible measures. <i>Nature Medicine</i> , <b>2021</b> , 27, 1034-1042	50.5	56
199	Serum tau and neurological outcome in cardiac arrest. <i>Annals of Neurology</i> , <b>2017</b> , 82, 665-675	9.4	55
198	CSF biomarkers: pinpointing Alzheimer pathogenesis. <i>Annals of the New York Academy of Sciences</i> , <b>2009</b> , 1180, 28-35	6.5	54
197	Discriminatory Analysis of Biochip-Derived Protein Patterns in CSF and Plasma in Neurodegenerative Diseases. <i>Frontiers in Aging Neuroscience</i> , <b>2011</b> , 3, 1	5.3	53
196	CSF/serum albumin ratio in dementias: a cross-sectional study on 1861 patients. <i>Neurobiology of Aging</i> , <b>2017</b> , 59, 1-9	5.6	52
195	Reduced cerebrospinal fluid BACE1 activity in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2009</b> , 15, 448-454	5.4	52
194	Serum but not cerebrospinal fluid levels of insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 (IGFBP-3) are increased in Alzheimer's disease. <i>Psychoneuroendocrinology</i> , <b>2013</b> , 38, 1729-37	5	51
193	Selective vulnerability in neurodegeneration: insights from clinical variants of Alzheimer's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2016</b> , 87, 1000-4	5.5	50
192	Predicting clinical decline and conversion to Alzheimer's disease or dementia using novel Elecsys A $\beta$ (1-42), pTau and tTau CSF immunoassays. <i>Scientific Reports</i> , <b>2019</b> , 9, 19024	4.9	50
191	Apathy and anxiety are early markers of Alzheimer's disease. <i>Neurobiology of Aging</i> , <b>2020</b> , 85, 74-82	5.6	50
190	Cerebrospinal fluid neurofilament light concentration in motor neuron disease and frontotemporal dementia predicts survival. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , <b>2017</b> , 18, 397-403	3.6	49
189	Peptidome analysis of cerebrospinal fluid by LC-MALDI MS. <i>PLoS ONE</i> , <b>2012</b> , 7, e42555	3.7	48
188	The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , <b>2021</b> , 17, 1145-1156	1.2	48
187	Time to Amyloid Positivity and Preclinical Changes in Brain Metabolism, Atrophy, and Cognition: Evidence for Emerging Amyloid Pathology in Alzheimer's Disease. <i>Frontiers in Neuroscience</i> , <b>2017</b> , 11, 281	5.1	47
186	Determining cut-points for Alzheimer's disease biomarkers: statistical issues, methods and challenges. <i>Biomarkers in Medicine</i> , <b>2012</b> , 6, 391-400	2.3	45
185	Mass spectrometric characterization of amyloid- $\beta$ species in the 7PA2 cell model of Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , <b>2013</b> , 33, 85-93	4.3	44
184	Predicting diagnosis and cognition with F-AV-1451 tau PET and structural MRI in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , <b>2019</b> , 15, 570-580	1.2	43

183	Emerging $\beta$ amyloid pathology and accelerated cortical atrophy. <i>JAMA Neurology</i> , <b>2014</b> , 71, 725-34	17.2	43
182	Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study. <i>Lancet Neurology</i> , <b>2021</b> , 20, 739-752	24.1	43
181	Chronic Depressive Symptomatology in Mild Cognitive Impairment Is Associated with Frontal Atrophy Rate which Hastens Conversion to Alzheimer Dementia. <i>American Journal of Geriatric Psychiatry</i> , <b>2016</b> , 24, 126-35	6.5	42
180	CSF biomarkers in neurodegenerative diseases. <i>Clinical Chemistry and Laboratory Medicine</i> , <b>2011</b> , 49, 345-52	5.9	42
179	Assessment of peptide chemical modifications on the development of an accurate and precise multiplex selected reaction monitoring assay for apolipoprotein e isoforms. <i>Journal of Proteome Research</i> , <b>2014</b> , 13, 1077-87	5.6	41
178	Cerebrospinal fluid biomarkers and cerebral atrophy in distinct clinical variants of probable Alzheimer's disease. <i>Neurobiology of Aging</i> , <b>2015</b> , 36, 2340-7	5.6	40
177	Determining clinically meaningful decline in preclinical Alzheimer disease. <i>Neurology</i> , <b>2019</b> , 93, e322-e333	3.5	40
176	Predicting Reduction of Cerebrospinal Fluid $\beta$ Amyloid 42 in Cognitively Healthy Controls. <i>JAMA Neurology</i> , <b>2015</b> , 72, 554-60	17.2	39
175	Increased amyloidogenic APP processing in APOE e4-negative individuals with cerebral $\beta$ amyloidosis. <i>Nature Communications</i> , <b>2016</b> , 7, 10918	17.4	39
174	Cerebrospinal fluid CXCL13 in Lyme neuroborreliosis and asymptomatic HIV infection. <i>BMC Neurology</i> , <b>2013</b> , 13, 2	3.1	38
173	Cerebrospinal fluid biomarkers of $\beta$ amyloid metabolism in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2013</b> , 19, 543-52	5	37
172	CSF protein biomarkers predicting longitudinal reduction of CSF $\beta$ amyloid42 in cognitively healthy elders. <i>Translational Psychiatry</i> , <b>2013</b> , 3, e293	8.6	37
171	Accelerating rates of cognitive decline and imaging markers associated with $\beta$ amyloid pathology. <i>Neurology</i> , <b>2016</b> , 86, 1887-96	6.5	37
170	Prevalence of the apolipoprotein E $\epsilon$ 4 allele in amyloid $\beta$ positive subjects across the spectrum of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , <b>2018</b> , 14, 913-924	1.2	36
169	Assessing risk for preclinical $\beta$ amyloid pathology with , cognitive, and demographic information. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , <b>2016</b> , 4, 76-84	5.2	36
168	Greater tau load and reduced cortical thickness in APOE $\epsilon$ 4-negative Alzheimer's disease: a cohort study. <i>Alzheimer's Research and Therapy</i> , <b>2018</b> , 10, 77	9	36
167	Effects of cerebrospinal fluid proteins on brain atrophy rates in cognitively healthy older adults. <i>Neurobiology of Aging</i> , <b>2014</b> , 35, 614-22	5.6	36
166	Exploring Alzheimer molecular pathology in Down's syndrome cerebrospinal fluid. <i>Neurodegenerative Diseases</i> , <b>2014</b> , 14, 98-106	2.3	36



165	Cerebrospinal fluid (CSF) 25-hydroxyvitamin D concentration and CSF acetylcholinesterase activity are reduced in patients with Alzheimer's disease. <i>PLoS ONE</i> , <b>2013</b> , 8, e81989	3.7	36
164	To know or not to know: ethical issues related to early diagnosis of Alzheimer's disease. <i>International Journal of Alzheimer's Disease</i> , <b>2010</b> , 2010,	3.7	36
163	Neuroinflammation in Lyme neuroborreliosis affects amyloid metabolism. <i>BMC Neurology</i> , <b>2010</b> , 10, 51	3.1	36
162	Proteomic profiling of cerebrospinal fluid in parkinsonian disorders. <i>Parkinsonism and Related Disorders</i> , <b>2010</b> , 16, 545-9	3.6	36
161	Amyloid- $\beta$ metabolism in Niemann-Pick C disease models and patients. <i>Metabolic Brain Disease</i> , <b>2012</b> , 27, 573-85	3.9	35
160	Leukocyte telomere length (LTL) is reduced in stable mild cognitive impairment but low LTL is not associated with conversion to Alzheimer's disease: a pilot study. <i>Experimental Gerontology</i> , <b>2012</b> , 47, 179-82	4.5	35
159	Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment. <i>Alzheimer's Research and Therapy</i> , <b>2021</b> , 13, 68	9	35
158	The implications of different approaches to define AT(N) in Alzheimer disease. <i>Neurology</i> , <b>2020</b> , 94, e22335-e2244	3.5	34
157	Individualized prognosis of cognitive decline and dementia in mild cognitive impairment based on plasma biomarker combinations. <i>Nature Aging</i> , <b>2021</b> , 1, 114-123		34
156	Untangling the association of amyloid- $\beta$ and tau with synaptic and axonal loss in Alzheimer's disease. <i>Brain</i> , <b>2021</b> , 144, 310-324	11.2	34
155	A novel quantification-driven proteomic strategy identifies an endogenous peptide of pleiotrophin as a new biomarker of Alzheimer's disease. <i>Scientific Reports</i> , <b>2017</b> , 7, 13333	4.9	33
154	Brain structure and function as mediators of the effects of amyloid on memory. <i>Neurology</i> , <b>2015</b> , 84, 1136-44	6.5	33
153	Elevated cerebrospinal fluid F2-isoprostane levels indicating oxidative stress in healthy siblings of multiple sclerosis patients. <i>Neuroscience Letters</i> , <b>2007</b> , 414, 233-6	3.3	32
152	Mild behavioral impairment and its relation to tau pathology in preclinical Alzheimer's disease. <i>Translational Psychiatry</i> , <b>2021</b> , 11, 76	8.6	32
151	Understanding the cause of sporadic Alzheimer's disease. <i>Expert Review of Neurotherapeutics</i> , <b>2014</b> , 14, 621-30	4.3	31
150	Cerebrospinal fluid biomarkers for Alzheimer disease and subcortical axonal damage in 5,542 clinical samples. <i>Alzheimer's Research and Therapy</i> , <b>2013</b> , 5, 47	9	31
149	Accurate risk estimation of $\beta$ amyloid positivity to identify prodromal Alzheimer's disease: Cross-validation study of practical algorithms. <i>Alzheimer's and Dementia</i> , <b>2019</b> , 15, 194-204	1.2	31
148	Plasma GFAP is an early marker of amyloid- $\beta$ but not tau pathology in Alzheimer's disease. <i>Brain</i> , <b>2021</b> ,	11.2	31



147	Reduced cerebrospinal fluid level of thyroxine in patients with Alzheimer's disease. <i>Psychoneuroendocrinology</i> , <b>2013</b> , 38, 1058-66	5	30
146	The transitional association between $\beta$ amyloid pathology and regional brain atrophy. <i>Alzheimer's and Dementia</i> , <b>2015</b> , 11, 1171-9	1.2	29
145	Cerebrospinal fluid analyses for the diagnosis of subarachnoid haemorrhage and experience from a Swedish study. What method is preferable when diagnosing a subarachnoid haemorrhage?. <i>Clinical Chemistry and Laboratory Medicine</i> , <b>2013</b> , 51, 2073-86	5.9	29
144	Converging molecular pathways in human neural development and degeneration. <i>Neuroscience Research</i> , <b>2010</b> , 66, 330-2	2.9	29
143	Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease: A Head-to-Head Comparison Against Amyloid Positron Emission Tomography and Magnetic Resonance Imaging. <i>JAMA Neurology</i> , <b>2021</b> , 78, 961-971	17.2	29
142	$\beta$ site amyloid precursor protein-cleaving enzyme 1 (BACE1) inhibitor treatment induces A $\beta$ -X peptides through alternative amyloid precursor protein cleavage. <i>Alzheimer's Research and Therapy</i> , <b>2014</b> , 6, 75	9	28
141	Interaction of Cigarette Smoking History With APOE Genotype and Age on Amyloid Level, Glucose Metabolism, and Neurocognition in Cognitively Normal Elders. <i>Nicotine and Tobacco Research</i> , <b>2016</b> , 18, 204-11	4.9	27
140	Altered cerebrospinal fluid levels of amyloid $\beta$ and amyloid precursor-like protein 1 peptides in Down's syndrome. <i>NeuroMolecular Medicine</i> , <b>2014</b> , 16, 510-6	4.6	26
139	CSF biomarkers for Alzheimer's pathology and the effect size of APOE e4. <i>Molecular Psychiatry</i> , <b>2014</b> , 19, 148-9	15.1	26
138	The influence of disease duration, clinical course, and immunosuppressive therapy on the synthesis of intrathecal oligoclonal IgG bands in multiple sclerosis. <i>Journal of Neuroimmunology</i> , <b>2013</b> , 264, 100-5	3.5	26
137	Performance of a guideline-recommended algorithm for prognostication of poor neurological outcome after cardiac arrest. <i>Intensive Care Medicine</i> , <b>2020</b> , 46, 1852-1862	14.5	25
136	Cerebrospinal fluid $\beta$ synuclein and Lewy body-like symptoms in normal controls, mild cognitive impairment, and Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , <b>2015</b> , 43, 1007-16	4.3	25
135	Cerebrospinal fluid brain injury biomarkers in children: a multicenter study. <i>Pediatric Neurology</i> , <b>2013</b> , 49, 31-39.e2	2.9	25
134	Biomarkers and cognitive endpoints to optimize trials in Alzheimer's disease. <i>Annals of Clinical and Translational Neurology</i> , <b>2015</b> , 2, 534-47	5.3	25
133	Cerebrospinal fluid concentrations of peptides derived from chromogranin B and secretogranin II are decreased in multiple sclerosis. <i>Journal of Neurochemistry</i> , <b>2007</b> , 103, 1932-9	6	25
132	Novel cerebrospinal fluid biomarkers of axonal degeneration in frontotemporal dementia. <i>Molecular Medicine Reports</i> , <b>2008</b> , 1, 757-61	2.9	24
131	Plasma biomarkers of Alzheimer's disease improve prediction of cognitive decline in cognitively unimpaired elderly populations. <i>Nature Communications</i> , <b>2021</b> , 12, 3555	17.4	23
130	Soluble P-tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau. <i>EMBO Molecular Medicine</i> , <b>2021</b> , 13, e14022	12	22

129	Cognitive and functional changes associated with A $\beta$ pathology and the progression to mild cognitive impairment. <i>Neurobiology of Aging</i> , <b>2016</b> , 48, 172-181	5.6	22
128	Cortical Atrophy is Associated with Accelerated Cognitive Decline in Mild Cognitive Impairment with Subsyndromal Depression. <i>American Journal of Geriatric Psychiatry</i> , <b>2017</b> , 25, 980-991	6.5	21
127	History of cigarette smoking in cognitively-normal elders is associated with elevated cerebrospinal fluid biomarkers of oxidative stress. <i>Drug and Alcohol Dependence</i> , <b>2014</b> , 142, 262-8	4.9	21
126	Automated cerebrospinal fluid cell count--new reference ranges and evaluation of its clinical use in central nervous system infections. <i>Clinical Biochemistry</i> , <b>2014</b> , 47, 25-30	3.5	21
125	Elevated cerebrospinal fluid levels of prostaglandin E2 and 15-(S)-hydroxyeicosatetraenoic acid in multiple sclerosis. <i>Journal of Internal Medicine</i> , <b>2009</b> , 265, 459-64	10.8	21
124	Carbon dioxide dynamics in relation to neurological outcome in resuscitated out-of-hospital cardiac arrest patients: an exploratory Target Temperature Management Trial substudy. <i>Critical Care</i> , <b>2018</b> , 22, 196	10.8	20
123	Proficiency testing programs for Alzheimer's disease cerebrospinal fluid biomarkers. <i>Biomarkers in Medicine</i> , <b>2012</b> , 6, 401-7	2.3	20
122	Lessons from Multicenter Studies on CSF Biomarkers for Alzheimer's Disease. <i>International Journal of Alzheimer's Disease</i> , <b>2010</b> , 2010,	3.7	20
121	Miglustat treatment may reduce cerebrospinal fluid levels of the axonal degeneration marker tau in niemann-pick type C. <i>JIMD Reports</i> , <b>2012</b> , 3, 45-52	1.9	19
120	CSF in Alzheimer's disease. <i>Advances in Clinical Chemistry</i> , <b>2014</b> , 65, 143-72	5.8	18
119	Biomarkers for microglial activation in Alzheimer's disease. <i>International Journal of Alzheimer's Disease</i> , <b>2011</b> , 2011, 939426	3.7	18
118	The accumulation rate of tau aggregates is higher in females and younger amyloid-positive subjects. <i>Brain</i> , <b>2020</b> , 143, 3805-3815	11.2	18
117	Amyloid pathology in the progression to mild cognitive impairment. <i>Neurobiology of Aging</i> , <b>2018</b> , 64, 76-84	5.6	17
116	Converging pathways of chromogranin and amyloid metabolism in the brain. <i>Journal of Alzheimer's Disease</i> , <b>2010</b> , 20, 1039-49	4.3	17
115	Data-driven approaches for tau-PET imaging biomarkers in Alzheimer's disease. <i>Human Brain Mapping</i> , <b>2019</b> , 40, 638-651	5.9	17
114	Associations between partial pressure of oxygen and neurological outcome in out-of-hospital cardiac arrest patients: an explorative analysis of a randomized trial. <i>Critical Care</i> , <b>2019</b> , 23, 30	10.8	16
113	Preclinical effects of APOE $\epsilon$ 4 on cerebrospinal fluid A $\beta$ 2 concentrations. <i>Alzheimer's Research and Therapy</i> , <b>2017</b> , 9, 87	9	16
112	Cerebrospinal fluid biomarkers of $\beta$ amyloid metabolism and neuronal damage in epileptic seizures. <i>European Journal of Neurology</i> , <b>2014</b> , 21, 486-91	6	16

111	Serum visinin-like protein-1 in concussed professional ice hockey players. <i>Brain Injury</i> , <b>2015</b> , 29, 872-6	2.1	15
110	Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies. <i>Nature Communications</i> , <b>2020</b> , 11, 6252	17.4	15
109	Relevance of biomarkers across different neurodegenerative diseases. <i>Alzheimer's Research and Therapy</i> , <b>2020</b> , 12, 56	9	15
108	β Amyloid pathology and hippocampal atrophy are independently associated with memory function in cognitively healthy elderly. <i>Scientific Reports</i> , <b>2019</b> , 9, 11180	4.9	15
107	Cerebrospinal fluid biomarkers in neurological diseases in children. <i>European Journal of Paediatric Neurology</i> , <b>2013</b> , 17, 7-13	3.8	15
106	Ex vivo O-labeling mass spectrometry identifies a peripheral amyloid β clearance pathway. <i>Molecular Neurodegeneration</i> , <b>2017</b> , 12, 18	19	15
105	The A4 study: β Amyloid and cognition in 4432 cognitively unimpaired adults. <i>Annals of Clinical and Translational Neurology</i> , <b>2020</b> , 7, 776-785	5.3	15
104	Serum levels of LIGHT in MS. <i>Multiple Sclerosis Journal</i> , <b>2013</b> , 19, 871-6	5	14
103	Comparing progression biomarkers in clinical trials of early Alzheimer's disease. <i>Annals of Clinical and Translational Neurology</i> , <b>2020</b> , 7, 1661-1673	5.3	14
102	Current advances in plasma and cerebrospinal fluid biomarkers in Alzheimer's disease. <i>Current Opinion in Neurology</i> , <b>2021</b> , 34, 266-274	7.1	14
101	Perspectives in fluid biomarkers in neurodegeneration from the 2019 biomarkers in neurodegenerative diseases course-a joint PhD student course at University College London and University of Gothenburg. <i>Alzheimer's Research and Therapy</i> , <b>2020</b> , 12, 20	9	13
100	Benchmarking biomarker-based criteria for Alzheimer's disease: Data from the Swedish Dementia Registry, SveDem. <i>Alzheimer's and Dementia</i> , <b>2015</b> , 11, 1470-1479	1.2	12
99	Biochemical markers in Alzheimer's disease clinical trials. <i>Biomarkers in Medicine</i> , <b>2010</b> , 4, 91-8	2.3	12
98	Use of theragnostic markers to select drugs for phase II/III trials for Alzheimer disease. <i>Alzheimer's Research and Therapy</i> , <b>2010</b> , 2, 32	9	12
97	Serum GFAP and UCH-L1 for the prediction of neurological outcome in comatose cardiac arrest patients. <i>Resuscitation</i> , <b>2020</b> , 154, 61-68	4	12
96	Plasma markers predict changes in amyloid, tau, atrophy and cognition in non-demented subjects. <i>Brain</i> , <b>2021</b> , 144, 2826-2836	11.2	12
95	Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma Aβ <sub>2</sub> /Aβ <sub>0</sub> and p-tau. <i>Alzheimer's and Dementia</i> , <b>2021</b> ,	1.2	12
94	Total-tau and neurofilament light in CSF reflect spinal cord ischaemia after endovascular aortic repair. <i>Neurochemistry International</i> , <b>2016</b> , 93, 1-5	4.4	11

93	Chronic depressive symptomatology and CSF amyloid beta and tau levels in mild cognitive impairment. <i>International Journal of Geriatric Psychiatry</i> , <b>2018</b> , 33, 1305-1311	3.9	11
92	Effects of baseline CSF $\beta$ synuclein on regional brain atrophy rates in healthy elders, mild cognitive impairment and Alzheimer's disease. <i>PLoS ONE</i> , <b>2013</b> , 8, e54443	3.7	11
91	Future screening for incipient Alzheimer's disease--the influence of prevalence on test performance. <i>European Neurology</i> , <b>2009</b> , 62, 200-3	2.1	11
90	Cerebrospinal fluid levels of neurogranin in Parkinsonian disorders. <i>Movement Disorders</i> , <b>2020</b> , 35, 513-518	11	11
89	A multicenter comparison of [ $^{18}$ F]flortaucipir, [ $^{18}$ F]RO948, and [ $^{18}$ F]MK6240 tau PET tracers to detect a common target ROI for differential diagnosis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2021</b> , 48, 2295-2305	8.8	11
88	Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease.. <i>JAMA Neurology</i> , <b>2021</b> ,	17.2	10
87	Early stages of tau pathology and its associations with functional connectivity, atrophy and memory. <i>Brain</i> , <b>2021</b> , 144, 2771-2783	11.2	10
86	Association Between Apolipoprotein E $\epsilon$ 4 vs $\epsilon$ 3, Age, and $\beta$ Amyloid in Adults Without Cognitive Impairment. <i>JAMA Neurology</i> , <b>2021</b> , 78, 229-235	17.2	10
85	Serum markers of brain injury can predict good neurological outcome after out-of-hospital cardiac arrest. <i>Intensive Care Medicine</i> , <b>2021</b> , 47, 984-994	14.5	10
84	Comparing the Clinical Utility and Diagnostic Performance of CSF P-Tau181, P-Tau217, and P-Tau231 Assays. <i>Neurology</i> , <b>2021</b> , 97, e1681-e1694	6.5	10
83	Effects of surgery and propofol-remifentanyl total intravenous anesthesia on cerebrospinal fluid biomarkers of inflammation, Alzheimer's disease, and neuronal injury in humans: a cohort study. <i>Journal of Neuroinflammation</i> , <b>2017</b> , 14, 193	10.1	9
82	The N-terminal domain of $\beta$ dystroglycan, released as a 38 kDa protein, is increased in cerebrospinal fluid in patients with Lyme neuroborreliosis. <i>Biochemical and Biophysical Research Communications</i> , <b>2011</b> , 412, 494-9	3.4	9
81	What is a certified reference material?. <i>Biomarkers in Medicine</i> , <b>2012</b> , 6, 369-70	2.3	9
80	Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum.. <i>JAMA Neurology</i> , <b>2022</b> ,	17.2	9
79	Plasma phosphorylated tau181 and neurodegeneration in Alzheimer's disease. <i>Annals of Clinical and Translational Neurology</i> , <b>2021</b> , 8, 259-265	5.3	9
78	Accelerated inflammatory aging in Alzheimer's disease and its relation to amyloid, tau, and cognition. <i>Scientific Reports</i> , <b>2021</b> , 11, 1965	4.9	9
77	Effects of APOE $\epsilon$ 4 on neuroimaging, cerebrospinal fluid biomarkers, and cognition in prodromal Alzheimer's disease. <i>Neurobiology of Aging</i> , <b>2018</b> , 71, 81-90	5.6	8
76	Mild dementia is associated with increased adrenal secretion of cortisol and precursor sex steroids in women. <i>Clinical Endocrinology</i> , <b>2011</b> , 75, 301-8	3.4	8

75	The Accu-Chek Mobile blood glucose monitoring system used under controlled conditions meets ISO 15197 standards in the hands of diabetes patients. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , <b>2012</b> , 72, 374-9	2	8
74	Association of Enlarged Perivascular Spaces and Measures of Small Vessel and Alzheimer Disease. <i>Neurology</i> , <b>2021</b> , 96, e193-e202	6.5	8
73	Tau PET correlates with different Alzheimer's disease-related features compared to CSF and plasma p-tau biomarkers. <i>EMBO Molecular Medicine</i> , <b>2021</b> , 13, e14398	12	8
72	The impact of demographic, clinical, genetic, and imaging variables on tau PET status. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2021</b> , 48, 2245-2258	8.8	8
71	Utility of plasma neurofilament light and total tau for clinical trials in Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , <b>2020</b> , 12, e12099	5.2	8
70	Blood-based biomarkers for Alzheimer's disease. <i>EMBO Molecular Medicine</i> , <b>2021</b> , e14408	12	7
69	Apolipoprotein E genotypes and longevity across dementia disorders. <i>Alzheimer's and Dementia</i> , <b>2018</b> , 14, 895-901	1.2	6
68	Cerebrospinal fluid analysis should be considered in patients with cognitive problems. <i>International Journal of Alzheimer's Disease</i> , <b>2010</b> , 2010, 163065	3.7	6
67	Differential expression of cerebrospinal fluid neuroinflammatory mediators depending on osteoarthritis pain phenotype. <i>Pain</i> , <b>2020</b> , 161, 2142-2154	8	6
66	Predictive Factors of Concerns about Falling in People with Parkinson's Disease: A 3-Year Longitudinal Study. <i>Parkinson's Disease</i> , <b>2019</b> , 2019, 4747320	2.6	6
65	Cerebrospinal fluid neurofilament light is associated with survival in mitochondrial disease patients. <i>Mitochondrion</i> , <b>2019</b> , 46, 228-235	4.9	5
64	Time between milestone events in the Alzheimer's disease amyloid cascade. <i>NeuroImage</i> , <b>2021</b> , 227, 117676	7.9	5
63	Preoperative sleep quality and adverse pain outcomes after total hip arthroplasty. <i>European Journal of Pain</i> , <b>2021</b> , 25, 1482-1492	3.7	5
62	CDH6 and HAGH protein levels in plasma associate with Alzheimer's disease in APOE $\epsilon$ carriers. <i>Scientific Reports</i> , <b>2020</b> , 10, 8233	4.9	4
61	Associations among amyloid status, age, and longitudinal regional brain atrophy in cognitively unimpaired older adults. <i>Neurobiology of Aging</i> , <b>2019</b> , 82, 110-119	5.6	4
60	The BIN1 rs744373 Alzheimer's disease risk SNP is associated with faster A $\beta$ -associated tau accumulation and cognitive decline. <i>Alzheimer's and Dementia</i> , <b>2021</b> ,	1.2	4
59	Reply: Do we still need positron emission tomography for early Alzheimer's disease diagnosis?. <i>Brain</i> , <b>2016</b> , 139, e61	11.2	4
58	Comparing ATN-T designation by tau PET visual reads, tau PET quantification, and CSF PTau181 across three cohorts. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2021</b> , 48, 2259-2271	8.8	4

57	Mild behavioral impairment is predictive of tau deposition in the earliest stages of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , <b>2020</b> , 16, e042595	1.2	3
56	Cerebrospinal fluid A $\beta$ <sub>2</sub> /A $\beta$ <sub>0</sub> and A $\beta$ <sub>2</sub> /A $\beta$ <sub>8</sub> as biomarkers of Alzheimer's disease. <i>Neurobiology of Aging</i> , <b>2016</b> , 39, S28	5.6	3
55	P4-137: THE TRANSITIONAL ASSOCIATION BETWEEN BETA-AMYLOID PATHOLOGY AND REGIONAL BRAIN ATROPHY <b>2014</b> , 10, P837-P838		3
54	Plasma amyloid- $\tau$ in patients with Tangier disease. <i>Journal of Alzheimer's Disease</i> , <b>2013</b> , 35, 307-12	4.3	3
53	$\tau$ <i>Neurology</i> , <b>2022</b> ,	6.5	3
52	Serum tau fragments as predictors of death or poor neurological outcome after out-of-hospital cardiac arrest. <i>Biomarkers</i> , <b>2019</b> , 24, 584-591	2.6	2
51	Acute reduction of cerebrospinal fluid volume prior to spinal anesthesia: implications for sensory block extent. <i>Minerva Anestesiologica</i> , <b>2020</b> , 86, 636-644	1.9	2
50	Plasma glial fibrillary acidic protein is an early marker of A $\beta$ pathology in Alzheimer's disease		2
49	The Effects of Tau, Amyloid, and White Matter Lesions on Mobility, Dual Tasking, and Balance in Older People. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , <b>2021</b> , 76, 683-694	6.4	2
48	Association of CSF A $\beta$ <sub>8</sub> Levels With Risk of Alzheimer Disease-Related Decline.. <i>Neurology</i> , <b>2021</b> ,	6.5	2
47	Fluid Biomarkers in Alzheimer's Disease and Frontotemporal Dementia <b>2018</b> , 221-252		1
46	Coagulation of cerebrospinal fluid--the Nonne-Froin sign. <i>Practical Neurology</i> , <b>2013</b> , 13, 273-4	2.4	1
45	Journal Watch: Our experts highlight the most important research articles across the spectrum of topics relevant to the field of neurodegenerative disease management. <i>Neurodegenerative Disease Management</i> , <b>2012</b> , 2, 351-354	2.8	1
44	Central nervous system monoaminergic activity in hip osteoarthritis patients with disabling pain: associations with pain severity and central sensitization.. <i>Pain Reports</i> , <b>2022</b> , 7, e988	3.5	1
43	Plasma amyloid, phosphorylated tau, and neurofilament light for individualized risk prediction in mild cognitive impairment		1
42	Data-driven approaches for Tau-PET imaging biomarkers in Alzheimer's disease		1
41	Cerebrospinal fluid p-tau <sub>217</sub> performs better than p-tau <sub>181</sub> as a biomarker of Alzheimer's disease		1
40	Time between milestone events in the Alzheimer's disease amyloid cascade		1



39	CSF A $\beta$ 8 levels are associated with Alzheimer-related decline: implications for $\beta$ -secretase modulators		1
38	DT-02-04: DETECTING BRAIN AMYLOID STATUS USING FULLY AUTOMATED PLASMA A $\beta$ BIOMARKER ASSAYS <b>2018</b> , 14, P1670-P1670		1
37	Plasma biomarkers of Alzheimer's disease predict cognitive decline and could improve clinical trials in the cognitively unimpaired elderly		1
36	Genetic effects on longitudinal cognitive decline during the early stages of Alzheimer's disease. <i>Scientific Reports</i> , <b>2021</b> , 11, 19853	4.9	0
35	Perceived walking difficulties in Parkinson's disease - predictors and changes over time. <i>BMC Geriatrics</i> , <b>2021</b> , 21, 221	4.1	0
34	Serum neurofilament light levels are correlated to long-term neurocognitive outcome measures after cardiac arrest.. <i>Brain Injury</i> , <b>2022</b> , 1-10	2.1	0
33	[O20505]: EFFECTS OF APOE E4 IN PRODROMAL ALZHEIMER'S DISEASE <b>2017</b> , 13, P562-P563		
32	Comparison of 18F-Flortaucipir visual assessment, SUVR quantification and CSF pTau for defining T-status in the AT(N) framework. <i>Alzheimers and Dementia</i> , <b>2020</b> , 16, e037276	1.2	
31	White matter lesions are associated with CSF biomarkers of neuroinflammation in prodromal Alzheimer's disease. <i>Alzheimers and Dementia</i> , <b>2020</b> , 16, e041795	1.2	
30	[P3032]: CSF BIOMARKERS OF NEUROINFLAMMATION ARE ELEVATED IN PRECLINICAL AND PRODROMAL AD AND CORRELATE WITH TAU PATHOLOGY <b>2017</b> , 13, P985-P985		
29	[P4097]: EMERGING AMYLOID PATHOLOGY <b>2017</b> , 13, P1340-P1340		
28	[P1075]: PREVALENCE OF THE APOLIPOPROTEIN E $\epsilon$ 4 ALLELE IN AMYLOID-POSITIVE SUBJECTS ACROSS THE SPECTRUM OF ALZHEIMER'S DISEASE <b>2017</b> , 13, P515-P515		
27	[P3075]: PLEIOTROPHIN, A NEW BIOMARKER FOR AD, IDENTIFIED USING A NOVEL STRATEGY IN CLINICAL PROTEOMICS <b>2017</b> , 13, P960-P961		
26	S5-01-03: CSF biomarkers versus PET biomarkers <b>2015</b> , 11, P302-P302		
25	Cerebrospinal fluid biomarkers to monitor treatment effects in Alzheimer's disease and related conditions. <i>Neurodegenerative Disease Management</i> , <b>2012</b> , 2, 117-123	2.8	
24	Journal Watch: Our panel of experts highlight the most important research articles across the spectrum of topics relevant to the field of neurodegenerative disease management. <i>Neurodegenerative Disease Management</i> , <b>2013</b> , 3, 105-107	2.8	
23	Journal Watch: Our panel of experts highlight the most important research articles across the spectrum of topics relevant to the field of neurodegenerative disease management.. <i>Neurodegenerative Disease Management</i> , <b>2013</b> , 3, 19-21	2.8	
22	Found in translation: a blood-based test for Niemann-Pick type C1. <i>Biomarkers in Medicine</i> , <b>2011</b> , 5, 201	2.3	



21	Journal Watch: Our panel of experts highlight the most important research articles across the spectrum of topics relevant to the field of neurodegenerative disease management. <i>Neurodegenerative Disease Management</i> , <b>2012</b> , 2, 451-453	2.8
20	Journal Watch: Our panel of experts highlight the most important research articles across the spectrum of topics relevant to the field of neurodegenerative disease management. <i>Neurodegenerative Disease Management</i> , <b>2012</b> , 2, 569-572	2.8
19	Components of gait in people with and without mild cognitive impairment.. <i>Gait and Posture</i> , <b>2022</b> , 93, 83-89	2.6
18	Cerebrospinal Fluid Biomarkers in Alzheimer’s Disease and Frontotemporal Dementia <b>2014</b> , 131-157	
17	P4-339: Early- and Late-Onset Alzheimer’s Disease are Associated with Distinct Regional TAU Pathology as Examined with [18]F-AV-1451 TAU Positron Emission Tomography <b>2016</b> , 12, P1164-P1165	
16	P2-167: Roadmap to the Biomarker-Based Diagnosis of Alzheimer’s Disease <b>2016</b> , 12, P679-P680	
15	O1-05-01: Increased Amyloidogenic app Processing in Apoe E4-Negative Individuals with Cerebral B-Amyloidosis <b>2016</b> , 12, P182-P182	
14	IC-P-002: : Roadmap to The Biomarker-Based Diagnosis of Alzheimer’s Disease <b>2016</b> , 12, P13-P13	
13	P2-142: Comparison of T-Tau, Neurogranin and NFL as CSF Neurodegeneration Markers in Alzheimer’s Disease <b>2016</b> , 12, P667-P667	
12	P4-536: CEREBROSPINAL FLUID BIOMARKERS FOR AMYLOID AND TAU USING FULLY AUTOMATED ASSAYS: ASSOCIATIONS WITH NEUROPATHOLOGY <b>2019</b> , 15, P1521-P1521	
11	DT-01-04: DIAGNOSTIC PERFORMANCE OF [18F]RO948 PET IN THE SEPARATION OF ALZHEIMER’S DISEASE FROM OTHER NEURODEGENERATIVE DISORDERS: FINDINGS FROM THE BIOFINDER-2 STUDY <b>2019</b> , 15, P1485-P1486	
10	P1-279: BIMODAL DISTRIBUTION OF THE CSF A $\beta$ 2/A $\beta$ 0 RATIO IN CLINICAL LABORATORY PRACTICE <b>2018</b> , 14, P389-P390	
9	DT-01-06: COGNITIVE DECLINE IN PRECLINICAL ALZHEIMER’S DISEASE: A COMPARISON AND SYNTHESIS OF LARGE INTERNATIONAL COHORTS <b>2018</b> , 14, P1667-P1668	
8	P1-430: EFFECTS OF APOE $\epsilon$ ON TAU, AMYLOID, ATROPHY AND COGNITION IN ALZHEIMER’S DISEASE <b>2018</b> , 14, P473-P474	
7	DT-01-01: DEVELOPMENT OF AB, TAU AND COGNITIVE CHANGES DURING THE TIME COURSE OF SPORADIC ALZHEIMER’S DISEASE <b>2018</b> , 14, P1665-P1665	
6	A new member in the biomarker discovery toolbox. <i>Biomarkers in Medicine</i> , <b>2011</b> , 5, 202	2.3
5	Troponin T: more than acute myocardial infarction. <i>Biomarkers in Medicine</i> , <b>2011</b> , 5, 203	2.3
4	Growth factors in Parkinson’s disease. <i>Biomarkers in Medicine</i> , <b>2011</b> , 5, 201-2	2.3

- 3 It is all about clearance. *Biomarkers in Medicine*, **2011**, 5, 202 2.3
- 2 Genetic influence during the early phases of Alzheimer's disease on longitudinal cognitive impairment.. *Alzheimer's and Dementia*, **2021**, 17 Suppl 3, e053474 1.2
- 1 Genetic interaction study of Alzheimer's disease quantitative biomarkers: A polygenic risk score analysis and evaluation.. *Alzheimer's and Dementia*, **2021**, 17 Suppl 3, e053556 1.2